← Back to Screener
Pluri Inc. Common Stock (PLUR)
Price$2.36
Value ScoreF
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-52.94%
Price vs S&P 500 (4W)-33.28%
VGM Score32.12
Market Capitalization$25.52M
All Metrics
Book Value / Share (Quarterly)$0.21
P/TBV (Annual)1.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)131.94%
Cash Flow / Share (Quarterly)$-2.13
Price vs S&P 500 (YTD)-31.35%
Gross Margin (TTM)40.16%
Net Profit Margin (TTM)-1936.30%
EPS (TTM)$-3.27
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-3.27
Revenue Growth (5Y)41.83%
EPS (Annual)$-3.63
ROI (Annual)-56.46%
Gross Margin (Annual)96.86%
Net Profit Margin (5Y Avg)-30867.06%
Cash / Share (Quarterly)$0.93
Revenue Growth QoQ (YoY)-37.93%
ROA (Last FY)-58.97%
Revenue Growth TTM (YoY)-20.87%
EBITD / Share (TTM)$-2.98
ROE (5Y Avg)-99.22%
Operating Margin (TTM)-1842.96%
Cash Flow / Share (Annual)$-2.49
P/B Ratio266.82x
P/B Ratio (Quarterly)2.84x
Net Income / Employee (Annual)$-181,100
EV / Revenue (TTM)39.64x
Net Interest Coverage (TTM)-36.45x
ROA (TTM)-74.16%
EPS Growth QoQ (YoY)35.93%
EPS Incl Extra (Annual)$-3.63
Current Ratio (Annual)0.69x
Quick Ratio (Quarterly)0.31x
3-Month Avg Trading Volume0.01M
52-Week Price Return-48.25%
Revenue / Employee (TTM)$10,600
Tangible BV / Share (Quarterly)$0.21
P/S Ratio (Annual)19.04x
Asset Turnover (Annual)0.03x
52-Week High$5.96
Operating Margin (5Y Avg)-30847.83%
EPS Excl Extra (Annual)$-3.63
CapEx CAGR (5Y)-5.19%
Tangible BV CAGR (5Y)-14.07%
26-Week Price Return-39.36%
Quick Ratio (Annual)0.68x
13-Week Price Return-34.31%
Total Debt / Equity (Annual)176.19x
Current Ratio (Quarterly)0.31x
Enterprise Value$53.52M
Revenue / Share Growth (5Y)10.64%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-33.61%
Revenue / Employee (Annual)$10,600
Pretax Margin (Annual)-1716.42%
Cash / Share (Annual)$2.66
3-Month Return Std Dev62.80%
Gross Margin (5Y Avg)88.18%
Net Income / Employee (TTM)$-205,800
ROE (Last FY)-133.14%
Net Interest Coverage (Annual)-16.32x
EPS Basic Excl Extra (Annual)$-3.63
Receivables Turnover (TTM)0.46x
Total Debt / Equity (Quarterly)260.33x
EPS Incl Extra (TTM)$-3.27
Receivables Turnover (Annual)0.48x
ROI (TTM)-61.52%
P/S Ratio (TTM)18.90x
Pretax Margin (5Y Avg)-30867.06%
Revenue / Share (Annual)$0.21
Tangible BV / Share (Annual)$0.32
Price vs S&P 500 (52W)-76.40%
EPS Growth TTM (YoY)35.10%
Year-to-Date Return-20.90%
5-Day Price Return0.21%
EPS Normalized (Annual)$-3.63
ROA (5Y Avg)-60.85%
Net Profit Margin (Annual)-1716.42%
Month-to-Date Return1.94%
Cash Flow / Share (TTM)$-0.70
EBITD / Share (Annual)$-3.42
Operating Margin (Annual)-1641.79%
LT Debt / Equity (Annual)176.19x
ROI (5Y Avg)-71.37%
LT Debt / Equity (Quarterly)260.33x
EPS Basic Excl Extra (TTM)$-3.27
P/TBV (Quarterly)2.84x
P/B Ratio (Annual)1.88x
Pretax Margin (TTM)-2009.63%
Book Value / Share (Annual)$0.32
Price vs S&P 500 (13W)-44.97%
Beta0.65x
Revenue / Share (TTM)$0.15
ROE (TTM)-53.15%
52-Week Low$2.22
vGradeF
gGradeC
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PLURPluri Inc. Common Stock | F | C | D | $2.36 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
Pluri Inc develops cell-based therapeutics using its proprietary 3D cell expansion platform, targeting regenerative medicine, immunotherapy, and hematologic diseases. The company generates revenue through CDMO services while advancing placenta-derived cell therapy candidates for inflammatory and musculoskeletal conditions. Pluri is also exploring applications in cultivated alternative proteins.